July 2nd 2025
The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
View More
Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights
View More
PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies
View More
Medical Crossfire®: Precision Medicine in Glioma Treatment—Integration of Molecular Profiling to Inform Targeted Therapies
View More
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options
View More
8th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes
View More
Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care
View More
Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma
View More
Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Polio-Rhinovirus Conjugate Receives Breakthrough Therapy Designation for Glioblastoma
May 20th 2016The US Food and Drug Administration granted the “breakthrough therapy” designation to a recombination poliovirus/rhinovirus conjugate known as PVS-RIPO, for treatment of recurrent glioblastoma multiforme.
Pediatric Neuro-Oncology: Time to Go Molecular
May 15th 2016One recurring theme from genomic studies of pediatric CNS tumors (and almost all cancers, for that matter) is that tumors that historically appeared to be a single entity based on examination under the microscope and routine immunohistochemical staining actually harbor molecularly distinct subgroups when analyzed by genomic sequencing techniques.
Chemotherapy After Radiation Increases Survival for Low-Grade Glioma Patients
April 13th 2016The combination of chemotherapy and radiation therapy resulted in longer overall survival than radiation alone in certain patients with grade 2 gliomas, according to long-term results from a randomized trial.
Vaccine Therapies Against Gliomas: Prime Time Yet?
March 15th 2016The promise of vaccine-based anticancer therapies has been explored for a number of years. However, the research met with little success in its early phases, largely because of a poor understanding of the biology of the immune system and its role in combatting cancer.
Gene-Mediated Cytotoxic Immunotherapy Improves Survival in Newly Diagnosed Glioma
November 22nd 2015Adding adjuvant gene-mediated cytotoxic immunotherapy using aglatimagene besadenovec and valacyclovir to standard of care improves survival among patients undergoing surgery for newly diagnosed malignant glioma.
Lomustine/Bevacizumab Fails to Improve Survival in Recurrent Glioblastoma
November 20th 2015Despite promising progression-free survival results, the combination of bevacizumab and lomustine for the treatment of first recurrence in glioblastoma did not improve overall survival, according to findings from the phase III EORTC-26101 trial.
Prognostic Factors for Germ Cell Tumor Patients With Brain Metastases
October 16th 2015A recent study highlights factors that predict worse prognosis for patients with germ cell tumors whose cancer has spread to the brain, including the presence of liver or bone metastases, multiple brain metastases, and others.